Welcome to our dedicated page for Azenta SEC filings (Ticker: AZTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for Azenta, Inc. (Nasdaq: AZTA), a life sciences company focused on cold-chain sample management and multiomics services. These regulatory documents offer detailed insight into how Azenta reports its financial performance, governance practices and executive compensation.
Core filings include the annual report on Form 10-K and quarterly updates on Form 10-Q, where Azenta discusses revenue from its Sample Management Solutions and Multiomics segments, separates products and services revenue, and explains trends in gross margin, operating expenses and adjusted EBITDA. Investors can review these filings to understand the contribution of sample storage, biorepository services and genomic analysis to the overall business.
Azenta’s current report filings on Form 8-K disclose material events such as quarterly and annual financial results, including segment performance and key metrics. For example, the company has furnished press releases detailing revenue growth, margin expansion and cash and liquidity positions, which are incorporated by reference into 8-K filings under Item 2.02.
The definitive proxy statement on Schedule 14A (DEF 14A) describes the structure of the Board of Directors, committee responsibilities, environmental, social and governance topics, and the executive compensation framework. It also outlines proposals submitted to shareholders, such as the election of directors, advisory votes on executive pay, amendments to the equity incentive plan and ratification of the independent auditor.
On Stock Titan, Azenta’s filings are updated as they appear on EDGAR, and AI-powered summaries can help explain lengthy documents like the 10-K, 10-Q, 8-K and DEF 14A. Users can quickly identify segment disclosures, non-GAAP reconciliations, compensation details and other key items without reading every page of the underlying filing.
Azenta, Inc. (AZTA)
Azenta, Inc. (AZTA)
Azenta, Inc. (AZTA) reported an insider equity transaction by its EVP, CFO and Treasurer, Lawrence Y. Lin. On 11/14/2025, 3,039 shares of common stock were withheld to cover tax obligations tied to the vesting of 10,566 restricted stock units on November 15, 2025. After this tax withholding event, the reporting person beneficially owned 42,974 shares of Azenta common stock directly. This filing reflects an administrative tax-related transaction rather than an open-market purchase or sale.
Azenta, Inc. (AZTA) president and CEO John Marotta reported a tax-related transaction involving 10,980 shares of common stock. On November 14, 2025, shares were withheld at a price of $29.75 per share to cover withholding taxes tied to the vesting of 27,872 restricted stock units on November 15, 2025. This Form 4 reflects an administrative share withholding for taxes rather than an open-market purchase or sale.
Azenta, Inc. (AZTA) reported an insider sale by an officer via an amended Form 4. The reporting person, SVP and CHRO, filed an amendment to include a Power of Attorney and to correct the transaction code to “S.”
The filing shows a sale of 1,085 shares of common stock at $28.54 on 08/12/2025, leaving 18,288 shares beneficially owned directly after the transaction. The amendment clarifies the sale code and formalizes signing authority; it does not change the reported share amounts.
Azenta, Inc. (AZTA) reported an amended Form 4 for its President and CEO, who is also a Director. The amendment corrects the transaction code to "P" for a purchase of 1,000 common shares at $25.99 on 06/02/2025. Following the transaction, the reporting person beneficially owned 107,295.78 shares, held directly.
The amendment also adds a Power of Attorney authorizing filings of Forms 3, 4, and 5 on the reporting person’s behalf.
Azenta, Inc. (AZTA) reported an amended Form 4 for a director reflecting a common stock purchase and administrative corrections. The filing shows the director acquired 12,000 common shares on 05/30/2025 at $26.65 per share. Following the transaction, the director beneficially owned 17,035 shares, held directly.
The amendment adds the Power of Attorney that was omitted from the original and corrects the transaction code previously reported as “A” to the correct code “P.”
Azenta, Inc. (AZTA) filed an amended Form 4 reporting an insider transaction by SVP and GM, Multiomics, Ginger Zhou. On 08/12/2025, a sale (transaction code S) of 1,085 shares of common stock was reported at a price of $28.54 per share.
Following the transaction, the reporting person beneficially owned 26,831 shares, held directly. The amendment also notes two administrative corrections: inclusion of a Power of Attorney that was omitted from the original filing on 08/13/2025, and correction of the transaction code from “D” to the correct code “S.”
Azenta insider sale tied to RSU vesting. Ginger Zhou, SVP and GM, Multiomics, disposed of 1,085 common shares on 08/12/2025 to satisfy withholding tax obligations arising from the vesting of 3,167 restricted stock units that vested on 08/09/2025. The reported sale price was $28.54 per share.
After the transaction the reporting person beneficially owned 26,831 shares. The Form 4 discloses this as a routine tax-withholding disposition rather than an open-market trading decision.
Azenta insider Olga Pirogova, who serves as SVP and CHRO, reported a disposition of common stock related to tax withholding on vested restricted stock units. The filing shows a sale of 1,085 shares at a reported price of $28.54 executed on 08/12/2025 to satisfy tax withholding obligations arising from the vesting on 08/09/2025 of 3,167 restricted stock units. After the transaction the reporting person beneficially owns 18,288 shares.
This is a routine, compensation-related sale rather than an unsolicited market disposition: the explanatory note explicitly states the sale was to meet withholding tax obligations on vested RSUs. No derivative transactions were reported in the filing.
FAQ
What is the current stock price of Azenta (AZTA)?
What is the market cap of Azenta (AZTA)?
